| Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer (NCT04759911) | M.D. Anderson Cancer Center | 2021-02-26 |
| Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial (NCT04284774) | National Cancer Institute (NCI) | 2020-10-13 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (NCT02465060) | National Cancer Institute (NCI) | 2015-08-17 |
| Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer (NCT02393690) | Academic and Community Cancer Research United | 2015-05-04 |
| Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer (NCT02152995) | National Cancer Institute (NCI) | 2014-08-14 |
| Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer (NCT01811212) | National Cancer Institute (NCI) | 2013-05-08 |
| Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors (NCT01709435) | National Cancer Institute (NCI) | 2012-11-14 |
| Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease (NCT01552434) | M.D. Anderson Cancer Center | 2012-10-16 |
| Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction (NCT01638533) | National Cancer Institute (NCI) | 2012-08-03 |
| Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy (NCT00729157) | National Cancer Institute (NCI) | 2008-08-01 |
| Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer (NCT00625846) | National Cancer Institute (NCI) | 2008-02-22 |
| Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine (NCT00559949) | National Cancer Institute (NCI) | 2007-12-01 |
| Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery (NCT00381641) | National Cancer Institute (NCI) | 2006-08-29 |